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Abstract 
Background: The majority of breast conserving surgery (BCS) is performed in younger women. There is little pub-
lished information about the views of women aged over 70 regarding BCS. The aim of this study was to investigate 
the attitudes of this age group towards BCS, and factors which may influence their treatment decision-making.
Methods: A questionnaire was sent to all patients who were aged 70 or over at the time they had breast cancer 
surgery in NHS Lanarkshire between 1999 and 2013. This detailed surgical options and recommendations, timing of 
decision making, treatment expectations, psychological and cosmetic concerns and other factors which may have 
influenced any decision made e.g. travel for radiotherapy and potential side effects.
Results: Responses were received from 339 patients, 192 of whom had a mastectomy with the remaining undergo-
ing BCS. In the mastectomy group 18 % (35) would have preferred to have BCS had it been an option, with 40 % (76) 
of group being happy to take neoadjuvant endocrine therapy to try and facilitate this. However, only 14 % (26) of 
patients would have considered neoadjuvant chemotherapy with the same aim. Almost half (82) of the mastectomy 
patients said that the risk of local recurrence following BCS was a factor which influenced their decision.
Conclusion: BCS is something that patients aged over 70 are interested in considering in the same way as younger 
patients. More than a third of patients requiring mastectomy would be willing to take neoadjuvant endocrine therapy 
to attempt to downstage their tumour to facilitate BCS.
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Background
At the current time 24 % of all breast cancer cases diag-
nosed in the United Kingdom are in women over the age 
of 75, and it is well established that that the risk of devel-
oping breast cancer increases with age (Cancer Research 
UK 2015). The number of new cases diagnosed in older 
women is predicted to rise by a factor of four over the 
next twenty-five years (Maddams et al. 2012).
Elderly patients differ in a number of important 
respects from younger women and these may affect the 
outcome of their breast cancer treatment. They have 
increased co-morbidities in addition to different psycho-
logical and functional profiles (physical capabilities and 
activities of daily living; Yancik et al. 2001). They are also 
less likely than younger women to ask questions or to 
seek a second opinion (Wyld and Reed 2003).
Various guidelines exist with regard to the treatment 
of older patients with breast cancer. These recommen-
dations tend to be based on extrapolated results from 
younger patients, or small retrospective sub-group analy-
sis due to lack of level 1 evidence in the older population 
as historically they have been excluded from randomised 
controlled trials (Biganzoli et  al. 2012). This is despite 
studies demonstrating that the elderly are willing to par-
ticipate in breast conservation trials (Silliman et al. 1993).
National Institute Clinical Excellence (NICE) guidelines 
on the diagnosis and treatment of locally advanced breast 
cancer (National Institute for Health and Care Excellence 
guidance 2009) state: “treat patients with early and locally 
invasive breast cancer, irrespective of age, with surgery 
and appropriate systemic therapy, rather than endocrine 
therapy alone, unless significant co-morbidity precludes 
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surgery”. This is mirrored by the updated (2012) Interna-
tional Society of Geriatric Oncology (SIOG) and Euro-
pean Society of Breast Cancer Specialists (EUSOMA) 
recommendations on the management of older women 
with breast cancer (Biganzoli et al. 2012). These state that 
“patients 70  years or older should be offered the same 
surgery as younger patients”, they go onto specify the 
standard of care to be breast conserving surgery (BCS) 
plus whole breast radiotherapy (WBRT) or mastectomy 
with or without radiotherapy. Indications for mastectomy 
are listed as large, or multifocal tumours not amena-
ble to BCS, patients not fit for WBRT, and most notably 
patients who prefer mastectomy to BCS and WBRT.
Even though age alone is not a contraindication for 
BCS (Morrow et  al. 1998) several retrospective studies 
have demonstrated that elderly women are less likely to 
be offered this option, with Repetto et  al. showing that 
BCS was undertaken in 71.1 % of women under the age 
of 50, and in only 26.1 % of women ≥70 (Repetto et  al. 
1997). Furthermore treatment decisions are often based 
on arbitrary reasons rather than evidence-based medi-
cine (Newschaffer et al. 1996).
Treatment of breast cancer by mastectomy or BCS 
are equally effective in terms of survival (Fentiman et al. 
2003). When BCS is followed by radiotherapy, local 
recurrence rate is no different than that following mas-
tectomy alone (Early Breast Cancer Trialists’ Collabo-
rative Group 1995). There is also evidence that women 
undergoing BCS have a better quality of life than those 
who had mastectomy (Curran et al. 1998).
To extend the use of BCS, there has been increasing use 
of both neoadjuvant chemotherapy and endocrine ther-
apy to reduce tumour size prior to surgery (Kurtz 1991; 
Fisher et  al. 1998; Mauriac et  al. 1991, 1999; Robertson 
et  al. 1992; Semiglazov et  al. 1994; Gazet et  al. 1994; 
Mustacchi et al. 1994; Bates et al. 1991). Endocrine ther-
apy is much better tolerated than chemotherapy which is 
important in elderly patients who may have other signifi-
cant co-morbidities. Tamoxifen was the first widely used 
neoadjuvant endocrine treatment and has been shown 
to be successful in elderly patients at reducing tumour 
size (Keen et al. 1997). This allowed inoperable tumours 
to become operable and tumours which would have 
required mastectomy to be removed by wide local exci-
sion (Gazet et al. 1994; Mustacchi et al. 1994; Bates et al. 
1991; Van Dalsen and de Vries 1995). More recent stud-
ies suggest that Letrozole is an even more effective agent 
in this regard in postmenopausal women with a higher 
response rate to treatment and more patients being able 
to have breast conservation (Eiermann et al. 2001).
Factors implicated in the decision making process 
for the treatment of breast cancer have been reviewed 
in the literature. Advice given by the surgeon (Rippy 
et  al. 2014) and age being quoted as important factors 
(Sio et  al. 2014). However, there is little specific to the 
elderly beyond one study reviewing the over 80s, which 
showed the risk/benefit profile of treatment, logistics 
(including transport), and psychosocial characteristics 
of the patients to be influential (Schonberg et  al. 2012). 
Meanwhile across a range of ages body image, survival 
benefit, risk of recurrence and quality of life have been 
highlighted as significant factors in a recent systematic 
review (Hamelinck et al. 2014).
There is little information in the literature about the 
views of women aged over 70 regarding BCS and the 
factors which influence their decision about which type 
of surgery to choose (Sandison et  al. 1996). Figueiredo 
investigated long-term body image and mental health 
in the elderly after breast cancer treatment, specifically 
considering whether patient preferences will predict 
post- treatment outcomes (Figueiredo et al. 2004). They 
concluded that body image is important for many older 
women and that considering their treatment preferences 
is important with regard to long-term mental health 
outcomes. Shared decision making should be a focus of 
treatment in older women.
The aim of this study was to investigate the attitudes 
towards BCS, and factors which may influence decision 
making in women over 70 with newly diagnosed breast 
cancer.
Methods
A database of all patients diagnosed with breast cancer 
across the three hospitals in NHS Lanarkshire is pro-
spectively maintained. From this patients aged 70 and 
over at the time of breast cancer diagnosis between 
1999 and 2013 were identified. Those who were treated 
operatively (mastectomy or BCS) were sent a question-
naire through the postal service (“Appendix”) covering 
potential surgical options and recommendations, timing 
of decisions made, treatment expectations, psychologi-
cal and cosmetic concerns and other factors which may 
have influenced decision making e.g. travel for radio-
therapy and potential side effects. The questionnaires 
were sent in two data sets, the first containing patients 
between 1999 and 2005, the second from 2006 to 2013. 
Responses were collected in 2005 and 2013 respectively 
and were entirely anonymous. The aim of the question-
naire was to ascertain why these patients chose to have 
their particular operation and what factors influenced 
their decision.
Patients excluded were men, those who had opted for 
primary endocrine treatment, patients unsuitable for 
operative treatment (e.g. advanced metastatic disease, 
inoperable tumours, significant co-morbidites precluding 
general anaesthetic), and death since diagnosis.
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Patients were asked to respond with “yes” or “no” to 
questions such as “did the surgeon explain the different 
surgical options for treating your breast cancer?”. A scale 
was provided with the options “very worried”, “fairly wor-
ried”, “slightly worried”, “not worried” or “indifferent” for 
questions relating to the psychological or cosmetic effects 
of their surgery. For questions relating to post operative 
appearance of their breasts the options provided were 
“very unhappy”, “unhappy”, “unsure”, “happy” and “very 
happy”. Outcome measures for factors associated with 
decision making were chosen based on those published 
in the literature (Rippy et al. 2014; Sio et al. 2014; Schon-
berg et al. 2012; Hamelinck et al. 2014) in addition to the 
results of a small pilot group which were surveyed prior 
to the study being commenced.
Questionnaires were analysed in two groups, mastec-
tomy vs. BCS. Statistical analysis was performed using 
Chi squared for comparison categorical proportions 
between the two groups. Students T test was utilised for 
comparing the continuous data related to tumour size. 
GraphPad Software (GraphPad software, Inc) was used 
for the calculations.
Ethical approval was sought and obtained from the 
local research ethics committee (LREC 06/S1001/10) and 
the NHS Trust research and development committee 
prior to the commencement of this project.
Results
Five hundred and thirty-two patients were identified as 
being 70 years of age or older at the time of their diagnosis 
and subsequent operative management for breast cancer, all 
of whom were sent questionnaire. The mean age of women 
in both the BCS and mastectomy groups was 76  years. 
Median ages were also comparable, interestingly being 
younger in the mastectomy group (75 years, range 70–100) 
than the BCS (76  years, range 70–94). Total tumour size 
(including ductal carcinoma in  situ) varied between the 
two groups with a mean of 20.4 mm in the BCS group, and 
29.6 mm in the mastectomy group (p ≤ 0.00001).
Responses were received from 339 patients (64 %) and, 
of these, 192 patients had a mastectomy (57 %) and 145 
had BCS performed (43  %). In the remaining two cases 
the patients did not indicate what surgery they had so 
were excluded from the main analysis. Unfortunately, 
due to the anonymisation of responses we are unable to 
provide any further information pertaining to the non-
responders group.
Table  1 summarises the key comparable findings 
between the two groups.
Treatment recommendations
Of the patients who had a mastectomy, 86 % (162) said that 
their surgeon had recommended this as the best surgical 
option; this was identical in those who underwent BCS 
(86 %, 118 patients). However, fewer patients in the mas-
tectomy group recalled their surgeon discussing different 
surgical treatment options than in the BCS group (58  %, 
112 vs. 70 %, 102; p = 0.02). This may reflect the fact that 
BCS may not have been an option for those who had a 
mastectomy. Twenty-six percent of patients (49 in the 
mastectomy group and 38 in BCS group) in both groups 
requested more information about the surgical options.
Treatment expectations
Patients in both groups expected that they would require 
mastectomy when first informed they had breast can-
cer. Interestingly, this was the case for significantly more 
patients (p = 0.0001) who had a mastectomy (64 %, 123 
patients) than patients who had BCS (33 %, 48 patients). 
Of the patients who had a mastectomy, only 26  % (50) 
had discussed the possibility of BCS pre-operatively with 
their surgeon. Eighteen per cent (35) of mastectomy 
patients said they would have preferred BCS if that had 
been a treatment option, the majority being unsure (118 
patients, 61 %).
Factors influencing decision making
Within the mastectomy group, 40  % (76 patients) said 
they would have been happy to take neoadjuvant endo-
crine therapy to shrink their tumour pre-operatively to 
facilitate BCS. However, only 14  % (26 patients) would 
have considered neoadjuvant chemotherapy with the 
same aim (Fig. 1).
Forty-three percent (82) of all mastectomy patients said 
that the possibility of local recurrence following BCS was 
a factor which influenced their treatment decision. Only 
15 % (28) of patients felt that having to travel for at least 
2 h per day to attend for post-operative radiotherapy put 
them off having BCS. A fifth of patients (39) felt that radi-
otherapy might have significant enough side effects to 
put them off having BCS (Fig. 2).
Although those within the mastectomy group were 
concerned about the side effects of radiotherapy, of the 
145 patients who had BCS, 40 (28  %) reported no side 
effects at all. The majority of those who had problems 
suffered only minor skin reddening or tiredness (52, 
36  %). Twelve people (8  %) had a poor cosmetic effect 
from breast shrinking or asymmetry as a result, with 14 
(10  %) suffering from more severe complications (lung, 
skin breakdown). Despite our patients having to travel a 
considerable distance daily to Glasgow for radiotherapy, 
only 4 % (6 patients) felt that this was a problem.
Cosmetic and psychological concerns
Interestingly, 38  % (74) of patients who opted to have a 
mastectomy and only 26  % (37) of patients undergoing 
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BCS were worried about the cosmetic effects of losing 
a breast (very worried, fairly worried and slightly wor-
ried), this was not statistically significant (p  =  0.013) 
(Fig.  3). Whereas concerns over the psychological con-
sequences of mastectomy were significant (p  =  0.0008) 
with 55 % (106) of mastectomy patients and 37 % (53) of 
BCS patients being worried that a mastectomy may have 
led to feelings of low self-esteem or depression (very wor-
ried, fairly worried and slightly worried; Fig. 4). It should 
also be noted that the level of non-response was much 
Table 1 Summary of comparable findings
Mastectomy BCS p value
Patient demographics
 Mean age 76 years 76 years Not significant
 Median age 75 years 76 years Not significant
 Age range 70–100 years 70–94 years
 Total tumour size 29.6 mm 20.4 mm p ≤ 0.00001
Treatment recommedations
 Underwent the recommended treatment 86 % 86 % Not significant
 Other treatments discussed 58 % 70 % p = 0.02
 More information requested 26 % 26 % Not significant
Treatment expectations
 Patients expected a mastectomy at diagnosis 64 % 33 % p = 0.0001
Cosmetic and psychological concerns
 Worried about the cosmetic effect of mastectomy 38 % 26 % p = 0.013








Neoadjuvant chemotherapy Neoadjuvant endocrine therapy
Yes No Unsure













Risk recurrence Inconvenience of travel Side effects of
radiotherapy
Fig. 2 Factors affecting decision in favour of mastectomy
Fig. 3 Cosmetic concerns associated with having a mastectomy
Fig. 4 Psychological concerns associated with having a mastectomy
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larger within the BCS group for both the cosmetic and 
psychological concerns (32 and 26 % respectively) when 
compared to the mastectomy group (3 and 2 %).
Of patients who had a wide local excision, 88 % (127) 
said they were happy with their decision to have BCS. Of 
these, 90 % (104) said they were happy or very happy with 
their cosmetic outcome. However, 8 % (9) of BCS patients 
reported being very unhappy with their cosmetic result 
(Fig. 5).
Discussion
Breast cancer incidence increases with age and is becom-
ing more common with the demographic shift to an older 
population. One-third of patients with breast cancer 
are aged 70 or over at the time of diagnosis (Ganz et al. 
1992). Many elderly patients continue to enjoy excellent 
physical and cognitive health well into their eighth and 
ninth decades making it appropriate that they receive 
treatment that gives long-term disease control and is to 
their satisfaction.
Treatment recommendations
It has been established that the use of primary endocrine 
therapy alone in patients who are fit for surgery and the 
reluctance to subject elderly patients to post-operative 
radiotherapy can no longer be justified (Horobin et  al. 
1991). There is no evidence that radiotherapy is less 
favourably tolerated by the elderly and, in fact there is 
evidence to the contrary (Dixon 1992). For this reason, 
mastectomy or wide local excision followed by post-
operative radiotherapy is the optimal treatment modal-
ity in elderly patients who are fit for surgery (Yiangou 
et al. 1996; Morris et al. 1997), as confirmed by the NICE 
guidelines (National Institute for Health and Care Excel-
lence guidance 2009) and recommendations from SIOG 
& EUSOMA (Biganzoli et al. 2012).
Eighty-six percent of out patients recalled being given 
a recommended treatment option by their surgeon, be 
it mastectomy or BCS, suggesting that our centres are 
complying with these guidelines. This is the case despite 
those within the mastectomy group being less likely to 
receive a choice of surgical options (p = 0.02), reflecting 
the lack of options within the group.
Elderly patients with breast cancer are less likely to be 
offered adjuvant chemotherapy than younger women 
for several reasons. They are perceived to be less likely to 
derive benefit from chemotherapy although most trials of 
chemotherapy exclude this age group. In addition increased 
co-morbidity leads to a greater risk of complications. This 
study indicates that only a few women (14  % of those 
undergoing mastectomy) would be prepared to consider 
neoadjuvant chemotherapy to downstage their tumour 
to facilitate BCS. Whereas the same patients are far more 
amenable to the use of neo-adjuvant endocrine therapy.
Treatment expectations
To date there is little published in the literature about the 
treatment expectations of the elderly. We have shown 
that patients in both groups initially expected to have 
mastectomy, although this was the case for significantly 
more patients who subsequently had a mastectomy 
(p = 0.0001). This maybe the case as breast conservation 
is a relatively new treatment, and that our patients were 
drawing treatment expectations from the treatment of 
the previous generation.
Factors influencing decision making
It is interesting to note that few studies have examined 
the issues surrounding patient choices about treatment 
in this age group. A small study (n = 50) of women aged 
over 70 with breast cancer which was published in 1996 
concluded that if given a choice, this age group would 
choose BCS and post-operative radiotherapy as opposed 
to modified radical mastectomy (Sandison et  al. 1996). 
However, two more studies reported that mastectomy 
was the more common choice for older women (Mon-
ypenny 2003; Wyld et al. 2004). This was considered to be 
because they presented with larger cancers which were 
unsuitable for BCS together with patient choice. The lat-
ter was thought to be due to the fact that elderly women 
were less concerned with body image and chose what 
they considered to be the more simple therapeutic option 
of mastectomy (Wyld et al. 2004). Older women may be 
particularly concerned about their ability to remain inde-
pendent when making treatment decisions. Therefore, if 
given a choice, many may prefer to have surgical treat-
ment that does not require additional procedures such as 
subsequent radiotherapy (Liang et al. 2002).
In this study, 40  % of the patients who had a mastec-
tomy said that they would have considered neoadjuvant 
endocrine therapy to facilitate BCS if that had been 
an option (Fig.  1). This was not routinely discussed as Fig. 5 Satisfaction with cosmetic results of BCS
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a potential treatment option during the whole study 
period. It is possible that using neoadjuvant endocrine 
therapy more frequently would increase the rate of BCS 
performed in this age group; however, clearly there would 
be cases in which this would not be appropriate.
Cosmetic and psychological concerns
This study identified a large proportion of elderly breast 
cancer patients that may be affected by psychological 
problems such as low self-esteem and depression, or 
worry about the cosmetic effects of losing a breast. This 
may be something that clinicians and breast care nurses 
need to focus on more when counselling elderly patients 
both before and after breast surgery. Women are better 
informed than ever about the various treatment options 
in breast cancer and alternatives to mastectomy. We have 
also demonstrated that BCS is something that women 
aged 70 and over are interested in discussing. It has been 
suggested that when asked retrospectively, patients tend 
to favour the treatment they have undergone because it 
is thought that if they were to prefer another treatment 
option over their own, this could lead to regret or con-
cern in thinking that their treatment was less than opti-
mal (de Haes et al. 2003). This may explain why a larger 
percentage of women (which was statistically significant) 
having a mastectomy (65 vs. 33  %) expected to need a 
mastectomy pre-operatively, even though we found 18 % 
of the mastectomy group who would have preferred to 
have BCS had it been an option. This was demonstrated 
to the point where 40  % would consider neoadjuvant 
endocrine treatment, and 14 % neoadjuvant chemother-
apy to help downstage their tumour to facilitate BCS. 
This could well be as a result of recall bias influenced by 
body image and the experience of mastectomy, in which 
case it is interesting to note what effect a mastectomy can 
have on elderly women.
Limitations
Attention must be drawn to the inherent weakness in 
this type of study. Given the retrospective data collec-
tion recall bias is an issue, which we have already men-
tioned. This could also be worsened in our patient 
group due to their advanced age and potential cogni-
tive impairment. We have attempted to reduce this by 
collecting the 14  years of data in two discreet groups, 
so that no patient had to recall a decision made over a 
decade previously. Clearly though 7 years is still a signifi-
cant period of time to recall details from an emotional 
diagnosis and subsequent treatment. Response bias may 
also have played a part, as those patients with extreme 
views towards their outcome (positive, or negative) may 
have been more inclined to respond than those who 
were content with their treatment outcome. In addition, 
as no clinical assessment of the tumours is kept within 
our database, particularly in terms of local invasion, we 
can make no assessment whether or not those patients 
in the mastectomy group were potential candidates for 
BCS or not. Clearly suitability for BCS will alter conver-
sations had at the initial diagnosis, and this could shape 
the patients perspective and views towards mastectomy 
as no other options are discussed.
Our response rate of 64  % could also be improved 
upon, but given the anonymous nature of our question-
naires, there was no way to track individual responses 
and pursue the non-responders accordingly. Despite 
these weaknesses, this is still a large sample (339 patients) 
of elderly patients expressing their views on their opera-
tive management, something that has not been seen to 
this scale before in the literature, and has an increasing 
impact in today’s population of breast cancer patients.
Conclusion
BCS is something that patients aged 70 and over are 
interested in discussing and considering in exactly the 
same way as their younger counterparts. In this study, 
more than a third of patients requiring mastectomy 
would have been willing to take neoadjuvant endocrine 
therapy to attempt to downstage their tumour to poten-
tially facilitate BCS. Although a few patients were put off 
by the requirement for post-operative radiotherapy, the 
majority of patients did not consider this to be a problem.
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Appendix
Breast cancer in patients over 70 years
Treatment / Surgery
1. Did your surgeon recommend any particular type of surgery at the time of diagnosis of 
your illness?                                                   Yes  □     No □
2. Did the surgeon explain about the different surgical options for treating your illness?
Yes □     No □ 
3. Were you keen to know about other available surgical options to treat your problem? 
Yes  □     No  □
4. Did you make your decision about the type of operation:
a. At the time of your clinic visit, when the surgeon told you about your illness and 
discussed different options of treatment Yes  □     No  □
b. After a few days                                                        Yes  □     No  □
5. What type of breast surgery did you have performed?
Mastectomy □ Please complete questions  22 -30
Breast conserving surgery □         Please complete questions 31-37
Patients who have had a mastectomy
6. When you were first told that you had breast cancer did you expect that you would 
need mastectomy as part of the treatment? Yes □  No  □
7. Did the surgeon you spoke to mention the possibility of breast conserving surgery as 
an option for your treatment? Yes □    No  □
8. Do you think that your decision to have a mastectomy was influenced by the surgeon 
explaining your different options? Yes □    No □
9. Would you have preferred to have breast conserving surgery than a mastectomy if this 
had been an option? Yes □    No  □
10.When you made your decision about the type of surgery how worried were you that 
having a mastectomy would have a psychological disadvantage to you (e.g. 
depression, low self-esteem, etc.)? 
Very worried □ Fairly worried □ Slightly worried □ Not worried □ Indifferent □
11.When you made your decision about the type of surgery how worried were you that 
having a mastectomy would have a cosmetic disadvantage to you?
Very worried □ Fairly worried □ Slightly worried □ Not worried □ Indifferent □
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12.If you were given the choice of having Chemotherapy or Tablets (e.g. Tamoxifen) with 
the aim to shrink the tumour and then try and perform breast conserving surgery would 
you have been keen to try this?                            
Chemotherapy Yes  □   No  □
Tamoxifen   Yes  □   No  □
13.Did the possibility that with breast conserving surgery you may still need a mastectomy 
in future in case of recurrence, make an important contribution for you to opt for a 
mastectomy? Yes  □   No  □
14.Did you think that the inconvenience of having to travel to Glasgow for Radiotherapy 
after breast conserving surgery and its possible side effects contributed significantly in 
your decision to opt for mastectomy?
Inconvenience of travel   Yes □    No □
Side effects of Radiotherapy       Yes □    No □ 
Patients who have had breast conserving surgery
15.When you were first told that you had breast cancer did you expect that you would 
need mastectomy as part of the treatment? Yes □     No  □
16.Are you happy with your decision to have breast conserving surgery?
Yes  □    No  □
17.When you made your decision about the type of surgery how worried were you that 
having a mastectomy would have a psychological disadvantage to you   (e.g. 
depression, low self-esteem, etc.)?
Very worried □ Fairly worried □ Slightly worried □ Not worried □ Indifferent □
18.When you made your decision about the type of surgery how worried were you that 
having a mastectomy would have a cosmetic disadvantage to you?
Very worried □ Fairly worried □ Slightly worried □ Not worried □ Indifferent □
19.How would you rate of how pleased you are with the appearance of your breast after 
surgery?
Very unhappy □  Unhappy □  Unsure □  Happy □  Very happy □
20.Did you have any side effects of radiotherapy?
None □  
Skin reddening / tiredness □ 
Shrinking of breast and asymmetry □  
Skin breakdown / lung complications □
21.Did you find travelling to Glasgow for radiotherapy a problem?
Yes □  No □
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